Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has recently published preclinical data in Cancer Cells that highlights the potential of its fusion protein candidate, mTNX-1700, to enhance immunotherapy in gastric cancer. The study, conducted in collaboration with Columbia University Medical School, demonstrated that mTNX-1700, which combines murine trefoil factor-2 (mTFF2) and murine serum albumin, significantly increased survival rates and reduced metastases in mouse models of gastric cancer. This breakthrough suggests that the human version, TNX-1700, could play a crucial role in overcoming checkpoint resistance in solid tumors, including gastric and colorectal cancers.

The implications of this research are profound, as it opens new avenues for treating cancers that have become resistant to current immunotherapy treatments. Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, emphasized the importance of these findings for the further development of TNX-1700. The ability to deplete immunosuppressive neutrophils and curb cancer-driven granulopoiesis represents a significant advancement in the fight against cancer, particularly for patients who have not responded to existing therapies.

This development is part of Tonix Pharmaceuticals’ broader effort to address some of the most challenging public health issues, including cancer, pain management, and infectious diseases. The company’s commitment to innovation is further evidenced by its upcoming submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TNX-102 SL, a product candidate for fibromyalgia management, which has received Fast Track designation from the FDA.

The potential of TNX-1700 to enhance the efficacy of anti-PD-1 immunotherapy could mark a turning point in cancer treatment, offering hope to patients with limited options. As Tonix Pharmaceuticals continues to advance its research and development efforts, the medical community eagerly anticipates the clinical outcomes of TNX-1700 in human trials.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Tonix Pharmaceuticals’ TNX-1700 Shows Promise in Enhancing Immunotherapy for Gastric Cancer.